当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.

A nationwide epidemiologic study of breast cancer incidence following breast reduction surgery in a large cohort of Swedish women.

Abstract：

:While it has been demonstrated that prophylactic mastectomy reduces breast cancer incidence among women at high risk, many women often consider this disfiguring surgery unacceptable. One alternative approach may be breast reduction surgery. In order to evaluate the long-term incidence of breast cancer following surgical removal of breast tissue, we have extended by 9 years the follow-up period of our earlier retrospective cohort study of Swedish women electing cosmetic breast reduction surgery (n=30,444) between 1965 and 1993, yielding an average of nearly 16 years of follow-up. Cancer incidence through 2002 was ascertained via the Swedish Cancer Registry. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated comparing women who underwent breast reduction surgery with women in the general Swedish population. Breast cancer was observed in 443 women versus 624 expected for a statistically significant reduced SIR of 0.71 (95% CI=0.65-0.78). Analyses by age at surgery, time since surgery or calendar year of surgery revealed similar reductions in risk. Our study of over 30,000 women with long-term follow-up offers further evidence that women undergoing breast reduction surgery have reduced breast cancer risk. As the evidence from large-scale cohort studies accumulates, direct testing of this reduction in risk through clinical trials should be considered.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Fryzek JP,Ye W,Nyrén O,Tarone RE,Lipworth L,McLaughlin JK

doi

10.1007/s10549-005-9099-2

subject

Has Abstract

pub_date

2006-05-01 00:00:00

pages

131-4

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

97

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR.

    abstract：:The research question of this investigation is whether the reduction rate of Ki-67 after neoadjuvant chemotherapy (NAC) could indicate a survival in patients with non-pCR. A total of 455 patients had received NAC, and subsequent surgery was analyzed retrospectively. Patients with non-pCR were divided into three subgro...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3084-6

    authors： Matsubara N,Mukai H,Masumoto M,Sasaki M,Naito Y,Fujii S,Wada N

    更新日期：2014-08-01 00:00:00

  • Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy.

    abstract：:A limited number of studies have associated adjuvant chemotherapy with structural brain changes. These studies had small sample sizes and were conducted shortly after cessation of chemotherapy. Results of these studies indicate local gray matter volume decrease and an increase in white matter lesions. Up till now, it ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1888-1

    authors： Koppelmans V,de Ruiter MB,van der Lijn F,Boogerd W,Seynaeve C,van der Lugt A,Vrooman H,Niessen WJ,Breteler MM,Schagen SB

    更新日期：2012-04-01 00:00:00

  • Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer.

    abstract：:Mastopathy is a common disease of the breast likely associated with elevated estrogen levels and a putative risk factor for breast cancer. The role of estrogen receptor alpha (ESR1) in mastopathy has not been investigated previously. Here, we investigated the prevalence of ESR1 gene amplification in mastopathy and its...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3427-y

    authors： Soysal SD,Kilic IB,Regenbrecht CR,Schneider S,Muenst S,Kilic N,Güth U,Dietel M,Terracciano LM,Kilic E

    更新日期：2015-06-01 00:00:00

  • The 17q23 amplicon and breast cancer.

    abstract：:A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1023081624133

    authors： Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期：2003-04-01 00:00:00

  • Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.

    abstract：:The spectrum of germline mutations among Jewish non Ashkenazi high risk breast/ovarian cancer families includes a few predominant mutations in BRCA1 (185delAG and Tyr978X) and BRCA2 (8765delAG). A few additional recurring mutations [A1708E, 981delAT, C61G (BRCA1) R2336P, and IVS2 + 1G > A (BRCA2)] have been reported i...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2006-8

    authors： Laitman Y,Simeonov M,Herskovitz L,Kushnir A,Shimon-Paluch S,Kaufman B,Zidan J,Friedman E

    更新日期：2012-06-01 00:00:00

  • MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status.

    abstract：:The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary lymphatic spread in breast cancer patients. Biopsies from breast cancer (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9400-z

    authors： Bathen TF,Jensen LR,Sitter B,Fjösne HE,Halgunset J,Axelson DE,Gribbestad IS,Lundgren S

    更新日期：2007-08-01 00:00:00

  • A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.

    abstract：:The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer. This phase 3, randomized, double-blind study directly compared time to progression (TTP) for exemestane and anastrozole therapy in this p...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-013-2573-3

    authors： Iwata H,Masuda N,Ohno S,Rai Y,Sato Y,Ohsumi S,Hashigaki S,Nishizawa Y,Hiraoka M,Morimoto T,Sasano H,Saeki T,Noguchi S

    更新日期：2013-06-01 00:00:00

  • Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.

    abstract：:The ErbB2 receptor is a proto-oncogene associated with a poor prognosis in breast cancer. Herceptin, the only humanized anti-ErbB2 antibody currently in clinical use, has proven to be an essential tool in the immunotherapy of breast carcinoma, but induces cardiotoxicity. ErbB2 is involved in the growth and survival pa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2103-8

    authors： Fedele C,Riccio G,Malara AE,D'Alessio G,De Lorenzo C

    更新日期：2012-07-01 00:00:00

  • A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management.

    abstract：PURPOSE:Choosing Wisely (CW)® was created by the American Board of Internal Medicine (ABIM) to promote patient-physician conversations about unnecessary medical interventions. Similarly, other countries created their own panels of experts called "CW® campaigns" which review recommendations submitted by that country's o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-06009-2

    authors： Shah H,Surujballi J,Awan AA,Hutton B,Arnaout A,Shorr R,Vandermeer L,Alzahrani MJ,Clemons M

    更新日期：2020-11-06 00:00:00

  • Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.

    abstract：:Irreversible electroporation (IRE) is a therapeutic technology for the ablation of soft tissues using electrodes to deliver intense but short electric pulses across a cell membrane, creating nanopores that lead to cell death. This phenomenon only affects the cell membrane, leaving the extracellular matrix and sensitiv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0803-5

    authors： Neal RE 2nd,Singh R,Hatcher HC,Kock ND,Torti SV,Davalos RV

    更新日期：2010-08-01 00:00:00

  • Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

    abstract：:The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described previously (Kaufman et...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-015-3633-7

    authors： Cortes J,Hudgens S,Twelves C,Perez EA,Awada A,Yelle L,McCutcheon S,Kaufman PA,Forsythe A,Velikova G

    更新日期：2015-12-01 00:00:00

  • Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.

    abstract：PURPOSE:The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several brea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4502-3

    authors： Kochi M,Iwamoto T,Niikura N,Bianchini G,Masuda S,Mizoo T,Nogami T,Shien T,Motoki T,Taira N,Tokuda Y,Doihara H,Matsuoka J,Fujiwara T

    更新日期：2018-01-01 00:00:00

  • Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.

    abstract：PURPOSE:APOBEC3B belongs to the family of DNA-editing enzymes. A copy number variant targeting the genomic APOBEC3A-APOBEC3B locus has a significant impact on breast cancer risk, but the relative contribution of APOBEC3B is uncertain. In this study, we investigate a loss-of-function mutation that selectively targets AP...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-016-4100-9

    authors： Radmanesh H,Spethmann T,Enßen J,Schürmann P,Bhuju S,Geffers R,Antonenkova N,Khusnutdinova E,Sadr-Nabavi A,Shandiz FH,Park-Simon TW,Hillemanns P,Christiansen H,Bogdanova N,Dörk T

    更新日期：2017-02-01 00:00:00

  • Effects of autotransplanted lymph node fragments on the lymphatic system in the pig model.

    abstract：:Secondary lymphedema often develops after removal of lymph nodes in combination with radiation therapy, in particular in patients with breast cancer, inguinal cancer, cervical cancer and melanoma. No convincing treatment for the prevention and therapy of acquired lymphedema exists so far, therefore we wanted to show t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0367-4

    authors： Blum KS,Hadamitzky C,Gratz KF,Pabst R

    更新日期：2010-02-01 00:00:00

  • Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.

    abstract：BACKGROUND:We recently showed PAM50 gene expression data can be represented by five quantitative, orthogonal, multi-gene breast tumor traits. These novel tumor 'dimensions' were superior to categorical intrinsic subtypes for clustering in high-risk breast cancer pedigrees, indicating potential to represent underlying g...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05097-5

    authors： Camp NJ,Madsen MJ,Herranz J,Rodríguez-Lescure Á,Ruiz A,Martín M,Bernard PS

    更新日期：2019-05-01 00:00:00

  • Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3.

    abstract：:Nicotine, a main addictive compound in tobacco smoke, has been linked to promotion and progression of lung, head and neck, pancreatic, and breast cancers, but the detailed mechanisms of cancer progression remain elusive. Here, we show that nicotine induces the expression of galectin-3 (an anti-apoptotic β-galactoside-...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2912-z

    authors： Guha P,Bandyopadhyaya G,Polumuri SK,Chumsri S,Gade P,Kalvakolanu DV,Ahmed H

    更新日期：2014-05-01 00:00:00

  • Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

    abstract：:We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-9503-3

    authors： Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

    更新日期：2004-10-01 00:00:00

  • Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.

    abstract：:Estrogenic steroids, such as estradiol, are known to play a crucial role in the development and growth of hormone-dependent breast cancer. Steroid sulfatase (STS) inhibitors that can prevent the biosynthesis of these steroids via the sulfatase pathway offer therapeutic potential. We show here the in vivo profile, incl...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9769-3

    authors： Foster PA,Chander SK,Parsons MF,Newman SP,Woo LW,Potter BV,Reed MJ,Purohit A

    更新日期：2008-09-01 00:00:00

  • Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.

    abstract：BACKGROUND:Women affected with breast cancer who carry a BRCA1 or BRCA2 (BRCA1/2) mutation are at risk of developing contralateral breast cancer. To reduce the risk of contralateral breast cancer, some patients opt for prophylactic surgery of the unaffected breast (contralateral prophylactic mastectomy, CPM) in additio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9423-5

    authors： Graves KD,Peshkin BN,Halbert CH,DeMarco TA,Isaacs C,Schwartz MD

    更新日期：2007-09-01 00:00:00

  • Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities.

    abstract：PURPOSE:The ER-/PR-/HER2- or triple-negative (TNBC) subtype is more prevalent among women who are young, black, Hispanic, and of lower SES. The purpose of this study is to determine if young age and low SES are associated with TNBC within four mutually exclusive race/ethnicities. METHODS:The study identified 19,283 ca...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4159-y

    authors： Parise CA,Caggiano V

    更新日期：2017-05-01 00:00:00

  • Serum concentration of tumor necrosis factor in patients with breast cancer.

    abstract：BACKGROUND:The outcome of breast cancer is usually determined by multiple factors. Serum tumor necrosis factor alpha concentration has been found to be increased in the circulation of patients with malignancy. This study was designed with the aim to investigate any correlation between the serum tumor necrosis factor al...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005736712307

    authors： Sheen-Chen SM,Chen WJ,Eng HL,Chou FF

    更新日期：1997-05-01 00:00:00

  • (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts.

    abstract：:(-)-Epigallocatechin (EGC), one of green tea polyphenols, has been shown to inhibit growth of cancer cells. However its mechanism of action is poorly known. We show here that EGC strongly inhibited the growth of breast cancer cell lines (MCF-7 and MDA-MB-231) but not that of normal breast epithelial cells. The inhibit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1020833410523

    authors： Vergote D,Cren-Olivé C,Chopin V,Toillon RA,Rolando C,Hondermarck H,Le Bourhis X

    更新日期：2002-12-01 00:00:00

  • Chemotherapy responsiveness of human breast tumors in the 6-day subrenal capsule assay: an update.

    abstract：:Feasibility of utilizing the 6-day subrenal capsule (SRC) assay to screen drugs against fresh surgical explants of human tumors was confirmed by testing six clinically active chemotherapeutic agents against 141 human breast cancers. Response rates of the six drugs obtained in the assay compared favorably with clinical...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806232

    authors： Bogden AE,Costanza ME,Reich SD,Griffin TW,Cobb WR

    更新日期：1983-01-01 00:00:00

  • Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

    abstract：:Adjuvant therapy for hormone receptor (HR) positive postmenopausal breast cancer patients includes aromatase inhibitors (AI). While both the non-steroidal AI letrozole and the steroidal AI exemestane decrease serum estrogen concentrations, there is evidence that exemestane may be less detrimental to bone. We hypothesi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3608-8

    authors： Oesterreich S,Henry NL,Kidwell KM,Van Poznak CH,Skaar TC,Dantzer J,Li L,Hangartner TN,Peacock M,Nguyen AT,Rae JM,Desta Z,Philips S,Storniolo AM,Stearns V,Hayes DF,Flockhart DA

    更新日期：2015-11-01 00:00:00

  • National consensus recommendations on patient-centered care for ductal carcinoma in situ.

    abstract：PURPOSE:The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS). METHODS:Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older wer...

    journal_title：Breast cancer research and treatment

    pub_type： 共识发展会议,杂志文章,评审

    doi：10.1007/s10549-019-05132-z

    authors： Gagliardi AR,Wright FC,Look Hong NJ,Groot G,Helyer L,Meiers P,Quan ML,Urquhart R,Warburton R

    更新日期：2019-04-01 00:00:00

  • Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.

    abstract：BACKGROUND:Paget's disease of the breast is an uncommon presentation of breast malignancy, accounting for 1-3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia. In the literature, differ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9880-5

    authors： Caliskan M,Gatti G,Sosnovskikh I,Rotmensz N,Botteri E,Musmeci S,Rosali dos Santos G,Viale G,Luini A

    更新日期：2008-12-01 00:00:00

  • The impact of sharing results of a randomized breast cancer clinical trial with study participants.

    abstract：BACKGROUND:There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and th...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-008-0057-7

    authors： Partridge AH,Wolff AC,Marcom PK,Kaufman PA,Zhang L,Gelman R,Moore C,Lake D,Fleming GF,Rugo HS,Atkins J,Sampson E,Collyar D,Winer EP

    更新日期：2009-05-01 00:00:00

  • Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study.

    abstract：:Seroma formation after axillary lymphadenectomy in women with breast cancer remains a problem despite many efforts to reduce surgery-related morbidity. In a prospective, randomised, open, parallel-group, controlled clinical trial we evaluated the effect of a fibrin-glue coated collagen patch (TachoComb H, Nycomed Phar...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1010671209279

    authors： Berger A,Tempfer C,Hartmann B,Kornprat P,Rossmann A,Neuwirth G,Tulusan A,Kubista E

    更新日期：2001-05-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract：:The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0080-8

    authors： Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期：2009-05-01 00:00:00

  • MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

    abstract：:Node-positive breast carcinoma is associated with a poor prognosis. Some patients benefit from adjuvant chemotherapy but new treatment modalities should still be developed in order to further increase the cure rate in this patient group. Prognostic factors are needed to define patients for such studies. Here, the prog...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006326513176

    authors： Talvensaari-Mattila A,Pääkkö P,Turpeenniemi-Hujanen T

    更新日期：1999-12-01 00:00:00